I have a short survey that will help validate how many people have been seriously injured by the COVID shots in the US. This survey will provide a cross-check on the family member survey I just did.
I know that yesterday you asked in your survey for US residents to respond about persons known to have been damaged by the vax and specifically for non US residents not to respond. I wondered if you had seen this report from the Australian Newspaper regarding the upsurge in "socio-emotional" disorders amongst Australian School children. Here is the link
In my own case however, 4 family members have suffered direct damage from the vax and one (1 year old) family member died. In addition 2 friends have suffered heart damage.
Peer-reviewed evidence demonstrates that COVID-19 vaccine-attributable deaths in Australia are exceptionally rare.
Robust population studies confirm that the vaccines significantly reduce both COVID-19-specific and all-cause mortality (Liu et al., 2023).
When fatal adverse events do occur, they are primarily linked to rare, specific conditions:
Thrombosis with Thrombocytopenia Syndrome (TTS)
Associated almost exclusively with the first dose of the AstraZeneca (Vaxzevria) vaccine. Risk-benefit modeling showed an extremely low incidence (< 3 per 100,000 first doses) with a case fatality rate of 5% to 6%, meaning deaths were estimated at less than 1 per million vaccinated individuals (Lau et al., 2021).
The benefits of preventing COVID-19 deaths heavily outweighed this risk (Lau et al., 2021).
Other Adverse Events of Special Interest (AESI)
In comprehensive state surveillance evaluations (such as Victoria's SAEFVIC data evaluated via WHO causality criteria), a minute number of deaths were confirmed as vaccine-attributable (Laemmle-Ruff et al., 2022).
Beyond TTS, these rare deaths were linked to severe presentations of Guillain-Barré Syndrome, acute disseminated encephalomyelitis, and myocarditis (Laemmle-Ruff et al., 2022).
Overall, Australian data confirms that the absolute risk of mortality from vaccination is fundamentally lower than the mortality risks associated with contracting SARS-CoV-2 (Lau et al., 2021; Liu et al., 2023).
References
Laemmle-Ruff, I., Lewis, G., Clothier, H. J., Dimaguila, G. L., Wolthuizen, M., Buttery, J., & Crawford, N. W. (2022). Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline. Frontiers in Public Health, 10. https://doi.org/10.3389/fpubh.2022.1053637
Lau, C. L., Mayfield, H. J., Sinclair, J. E., Brown, S. J., Waller, M., Enjeti, A. K., Baird, A., Short, K. R., Mengersen, K., & Litt, J. (2021). Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework. Vaccine, 39(51), 7429-7440. https://doi.org/10.1016/j.vaccine.2021.10.079
Liu, B., Stepien, S., Dobbins, T., Gidding, H., Henry, D., Korda, R., Mills, L., Pearson, S. A., Pratt, N., Vajdic, C. M., Welsh, J., & Macartney, K. (2023). Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. The Lancet Regional Health - Western Pacific, 40, 100928. https://doi.org/10.1016/j.lanwpc.2023.100928
What about EMT, Paramedics or the Billing, Coding, Insurance folks behind Ambulance services...ask us folks..some have things to share.
I also have a family member who had strokes and a heart attack after many shots. Nothing before.
I know that yesterday you asked in your survey for US residents to respond about persons known to have been damaged by the vax and specifically for non US residents not to respond. I wondered if you had seen this report from the Australian Newspaper regarding the upsurge in "socio-emotional" disorders amongst Australian School children. Here is the link
https://www.theaustralian.com.au/education/socioemotional-disorders-drive-record-surge-in-student-disability-since-pandemic/news-story/602b616e6ca694da7d53dc6854b7f05c.
In my own case however, 4 family members have suffered direct damage from the vax and one (1 year old) family member died. In addition 2 friends have suffered heart damage.
Peer-reviewed evidence demonstrates that COVID-19 vaccine-attributable deaths in Australia are exceptionally rare.
Robust population studies confirm that the vaccines significantly reduce both COVID-19-specific and all-cause mortality (Liu et al., 2023).
When fatal adverse events do occur, they are primarily linked to rare, specific conditions:
Thrombosis with Thrombocytopenia Syndrome (TTS)
Associated almost exclusively with the first dose of the AstraZeneca (Vaxzevria) vaccine. Risk-benefit modeling showed an extremely low incidence (< 3 per 100,000 first doses) with a case fatality rate of 5% to 6%, meaning deaths were estimated at less than 1 per million vaccinated individuals (Lau et al., 2021).
The benefits of preventing COVID-19 deaths heavily outweighed this risk (Lau et al., 2021).
Other Adverse Events of Special Interest (AESI)
In comprehensive state surveillance evaluations (such as Victoria's SAEFVIC data evaluated via WHO causality criteria), a minute number of deaths were confirmed as vaccine-attributable (Laemmle-Ruff et al., 2022).
Beyond TTS, these rare deaths were linked to severe presentations of Guillain-Barré Syndrome, acute disseminated encephalomyelitis, and myocarditis (Laemmle-Ruff et al., 2022).
Overall, Australian data confirms that the absolute risk of mortality from vaccination is fundamentally lower than the mortality risks associated with contracting SARS-CoV-2 (Lau et al., 2021; Liu et al., 2023).
References
Laemmle-Ruff, I., Lewis, G., Clothier, H. J., Dimaguila, G. L., Wolthuizen, M., Buttery, J., & Crawford, N. W. (2022). Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline. Frontiers in Public Health, 10. https://doi.org/10.3389/fpubh.2022.1053637
Lau, C. L., Mayfield, H. J., Sinclair, J. E., Brown, S. J., Waller, M., Enjeti, A. K., Baird, A., Short, K. R., Mengersen, K., & Litt, J. (2021). Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework. Vaccine, 39(51), 7429-7440. https://doi.org/10.1016/j.vaccine.2021.10.079
Liu, B., Stepien, S., Dobbins, T., Gidding, H., Henry, D., Korda, R., Mills, L., Pearson, S. A., Pratt, N., Vajdic, C. M., Welsh, J., & Macartney, K. (2023). Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. The Lancet Regional Health - Western Pacific, 40, 100928. https://doi.org/10.1016/j.lanwpc.2023.100928